Float Short %

16.71

Margin Of Safety %

Put/Call OI Ratio

0.55

EPS Next Q Diff

0.36

EPS Last/This Y

EPS This/Next Y

3.87

Price

91.87

Target Price

133.41

Analyst Recom

1.06

Performance Q

2.18

Relative Volume

1.22

Beta

1.03

Ticker: AXSM

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2024-12-19	AXSM	89.68	0.81	0.44	55122
2024-12-20	AXSM	90.84	0.70	1.42	60117
2024-12-23	AXSM	86.87	0.61	0.45	45790
2024-12-24	AXSM	86.29	0.58	0.23	53070
2024-12-26	AXSM	88.02	0.58	0.49	53217
2024-12-27	AXSM	86.69	0.59	0.60	54006
2024-12-30	AXSM	84.77	0.59	0.81	54470
2024-12-31	AXSM	84.65	0.52	0.21	49688
2025-01-02	AXSM	87.32	0.52	1.27	48758
2025-01-03	AXSM	86.45	0.55	1.39	50513
2025-01-06	AXSM	85.17	0.56	0.36	50950
2025-01-07	AXSM	83.75	0.56	0.14	52052
2025-01-08	AXSM	82.55	0.55	0.38	52497
2025-01-09	AXSM	82.57	0.55	0.42	52497
2025-01-10	AXSM	80.03	0.54	1.17	53221
2025-01-13	AXSM	89.4	0.56	0.19	53976
2025-01-14	AXSM	84.66	0.54	0.07	54917
2025-01-15	AXSM	93.78	0.55	0.13	54482
2025-01-16	AXSM	93.74	0.55	0.12	54835
2025-01-17	AXSM	91.87	0.55	0.56	55083
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2024-12-19	AXSM	89.62	50.7	330.3	-5.27
2024-12-20	AXSM	90.88	50.7	330.9	-5.27
2024-12-23	AXSM	86.95	50.7	329.5	-5.27
2024-12-24	AXSM	87.01	50.7	330.6	-5.27
2024-12-26	AXSM	87.97	50.7	330.8	-5.27
2024-12-27	AXSM	86.68	50.7	330.2	-5.27
2024-12-30	AXSM	84.68	50.7	330.0	-5.27
2024-12-31	AXSM	84.75	50.7	330.6	-5.27
2025-01-02	AXSM	87.32	50.7	331.4	-5.27
2025-01-03	AXSM	86.44	50.7	330.3	-5.27
2025-01-06	AXSM	85.21	50.7	330.2	-5.27
2025-01-07	AXSM	83.74	50.7	330.2	-5.27
2025-01-08	AXSM	82.57	50.7	330.2	-5.27
2025-01-09	AXSM	82.57	50.7	330.6	-5.27
2025-01-10	AXSM	80.01	50.7	329.8	-5.27
2025-01-13	AXSM	89.33	50.7	333.5	-5.27
2025-01-14	AXSM	84.66	50.7	329.3	-5.27
2025-01-15	AXSM	93.81	50.7	333.3	-5.27
2025-01-16	AXSM	93.63	50.7	330.5	-5.27
2025-01-17	AXSM	91.87	50.6	330.1	-5.27
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2024-12-19	AXSM	-0.66	-5.57	17.86
2024-12-20	AXSM	-0.66	-5.57	17.86
2024-12-23	AXSM	-0.65	-5.57	17.86
2024-12-24	AXSM	-0.65	-5.57	17.86
2024-12-26	AXSM	-0.66	-5.57	16.45
2024-12-27	AXSM	-0.66	-5.57	16.45
2024-12-30	AXSM	-0.67	-5.57	16.45
2024-12-31	AXSM	-0.67	-5.57	16.45
2025-01-02	AXSM	-0.66	-5.57	16.45
2025-01-03	AXSM	-0.66	-5.57	16.45
2025-01-06	AXSM	-0.67	-5.60	16.45
2025-01-07	AXSM	-0.67	-5.60	16.45
2025-01-08	AXSM	-0.66	-5.60	16.45
2025-01-09	AXSM	-0.66	-5.60	16.45
2025-01-10	AXSM	-0.66	-5.60	16.45
2025-01-13	AXSM	-0.66	-5.62	16.71
2025-01-14	AXSM	-0.66	-5.62	16.71
2025-01-15	AXSM	-0.66	-5.62	16.71
2025-01-16	AXSM	-0.66	-5.62	16.71
2025-01-17	AXSM	-0.66	-5.62	16.71
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-1.34

Avg. EPS Est. Current Quarter

-1.03

Avg. EPS Est. Next Quarter

-0.98

Insider Transactions

-0.66

Institutional Transactions

-5.62

Beta

1.03

Average Sales Estimate Current Quarter

117

Average Sales Estimate Next Quarter

121

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

16.1

Max Drawdown 5-Year %

-79.8

Target Price

133.41

P/E

Forward P/E

PEG

P/S

13.16

P/B

47.93

P/Free Cash Flow

EPS

-6.54

Average EPS Est. Cur. Y

-5.27

EPS Next Y. (Est.)

-1.4

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-91.87

Relative Volume

1.22

Return on Equity vs Sector %

-353.8

Return on Equity vs Industry %

-341.2

EPS 1 7Days Diff

EPS 1 30Days Diff

0.3

EBIT Estimation

330.1

Axsome Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 607

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

stock quote shares AXSM – Axsome Therapeutics, Inc. Stock Price stock today

news today AXSM – Axsome Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch AXSM – Axsome Therapeutics, Inc. yahoo finance google finance

stock history AXSM – Axsome Therapeutics, Inc. invest stock market

stock prices AXSM premarket after hours

ticker AXSM fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: AXSM

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y